Depot-medroxy progesterone acetate as contraceptive: study at tertiary care centre


  • Neena Gupta Department of Obstetrics and Gynaecology, GSVM, Kanpur, Uttar Pradesh, India
  • Divya Diwedi Department of Obstetrics and Gynaecology, GSVM, Kanpur, Uttar Pradesh, India
  • Neha Sharma Department of Obstetrics and Gynaecology, GSVM, Kanpur, Uttar Pradesh, India
  • Uruj Jahan Department of Obstetrics and Gynaecology, GSVM, Kanpur, Uttar Pradesh, India



DMPA, Contraception, Acceptability, Side effects, Postpartum period, Interval, Postabortal


Background: The aim was to study the acceptability, efficacy and side effects of Depot-medroxy progesterone acetate (DMPA) as contraceptive in postpartum, interval and postabortal period.

Methods: The present study was a prospective longitudinal study conducted in the department of obstetrics and gynaecology, GSVM medical college, Kanpur. Total 300 patients were counselled out of which 141 enrolled in the study during a period of January 2019 to September 2020. All reproductive age group (18-45) women who were willing to use DMPA for contraception in postpartum period, postabortal period or in interval period and also ready for follow up were included in the study. At the time of 1st dose DMPA card issued to patient where her particulars, weight, blood pressure, menstrual complaints were recorded. Date of next visit was also mentioned.

Results: Despite of benefits and proper counselling, less number of patients (47%) opted for DMPA as contraception. Acceptance (55%) and continuation rate for further doses (36.3% for 4th dose) was maximum in the postpartum period among the three groups taken in our study (postpartum, interval and postabortal). Menstrual changes were the most common reasons for discontinuation (39.7%) in all three groups. Other minor side effects may include change in weight and mood swings.

Conclusions: When patients were counselled immediately after delivery, many of them gave positive note, but actual time of application is after 6 weeks postpartum where less number of patients turned up for DMPA. There is a need to create awareness regarding the harmless side effects.

Author Biography

Neha Sharma, Department of Obstetrics and Gynaecology, GSVM, Kanpur, Uttar Pradesh, India

Junior resident

GSVM Kanpur


Ministry of Health and Family Welfare, Government of India. Reference Manual for Injectable Contraceptive (DMPA). Available at: accessed on 14 February 2022.

Khan ME, Bhatnagar I. Challenges in introducing new contraceptive methods: a case study of India. Int Q Community Health Educ. 2015;35(4):387-401.

United Nations. Department of Economic and Social Affairs, Population Division. Contraceptive Use by Method. Data Booklet. Available at:>pdf. Accessed on 14 February 2022.

Cameron ST, Craig A, Sim J, Gallimore A, Cowan S, Dundas K, et al. Feasibility and acceptability of introducing routine antenatal contraceptive counselling and provision of contraception after delivery: the APPLES pilot evaluation. BJOG. 2017;124(13):2009-15.

Khelifi A. Contraception by injectable progestin. depo provera-opportunity. Continuity Analysis Situat Central West Tunisia. 1997:6:16-7.

Population Foundation India. Fact sheet: Evidence on contraceptive mrthod mix in developing countries: south/South East Asia. Available at: Accessed on 14 February 2022.

Khan ME, Dixit A, Ahmad J, Pillai G. Introduction of DMPA in public health facilities of Uttar Pradesh and Rajasthan: an evaluation. New Delhi: Population Council; 2015.

Purwandari ES, Setyowati A. Correlation use of injectable contraceptive types with menstruation pattern changes in contraception acceptor. Joint Int Confer. 2018;2(2):799-803.

Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long term acceptors. Contraception. 1999;59(5):301-3.

Patel A, Thakkar J, Patel MS. A study of use of DMPA (injectable contraceptive) in postpartum and postabortal patients. Int J Scientif Res. 2019;8(11).






Original Research Articles